London, United Kingdom
LabGenius Therapeutics, founded in 2012, is a drug discovery company based in the United Kingdom. It focuses on the development of next-generation therapeutic antibodies utilizing its advanced EVA™ platform, which combines artificial intelligence, robotic automation, and synthetic biology. This platform is designed to be modality and format-agnostic, specifically enhancing selectivity in antibodies aimed at treating solid tumors.
With a focus on delivering a pipeline characterized by antibodies boasting best-in-class killing profiles, LabGenius operates within several synergistic industries, including AI, Biotechnology, Health and Wellness, Robotics, and Machine Learning. The company's unique approach positions it as a pioneer in the therapeutic discovery landscape.
In its latest funding round, LabGenius secured a £35.00M Series B investment, backed by reputable investors, such as Kindred Capital, Octopus Ventures, Lux Capital, Obvious Ventures, Atomico, LG Corp., MERL Ventures Fund, and Recode Health Ventures. This infusion of capital fortifies the company's capabilities for further innovation and market expansion.
